Obesity and metabolic disease new drug development corporations D&D Pharmatech is up more than 11% in early trading. On expectations for its fatty liver inflammation therapy clinical trial, buying is pouring in for a second day.
As of 10:01 a.m., on the KOSDAQ market, D&D Pharmatech is trading at 110,000 won, up 11,200 won (11.34%) from the previous session. D&D Pharmatech even hit the upper price limit the day before after related news spread.
D&D Pharmatech earlier said at the European Association for the Study of the Liver (EASL) that in phase 2 of the clinical trial for its metabolic dysfunction-associated steatohepatitis (MASH) drug candidate "DD01," it met all key histological endpoints.
Heo Hyemin, a Kiwoom Securities analyst, said, "It secured statistical significance in the three biopsy endpoints that matter most in MASH drug development, including simultaneously achieving MASH resolution and fibrosis improvement," and noted, "We judge that its technology transfer negotiating power has increased, and that interest from academia and global big pharma will expand."